Skip to content

Endovascular reperfusion followed by Immediate Acupuncture for Acute Ischemic Stroke: a multi-center randomized controlled trial

Endovascular reperfusion followed by Immediate Acupuncture for Acute Ischemic Stroke: a multi-center randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000893
Enrollment
Unknown
Registered
2026-04-03
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute anterior circulation large vessel occlusion stroke

Interventions

Acupuncture :Acupuncture + Endovascular thrombectomy and standard treatment.
Sham Acupuncture :Sham acupuncture + endovascular thrombectomy and standard treatment.

Sponsors

Hospital of Chengdu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)Age: 18–80 years; 2)Presenting with acute ischemic stroke (AIS) symptoms within 24 hours from symptom onset or time last known well; 3)Free of disability before the stroke onset (mRS score of 0-1) 4)Baseline National Institutes of Health Stroke Scale (NIHSS) score between 5 and 25; 5)Occlusion of the intracranial internal carotid artery, M1 segment or M2 segment of middle cerebral artery (MCA), as confirmed by CTA, MRA or DSA; 6)Baseline Alberta Stroke Program Early CT Score (ASPECTS) = 6 based on non-contrast computed tomography (NCCT); 7)Treated with emergency EVT resulting in near-complete to complete recanalization (expanded Thrombolysis In Cerebral Infarction [eTICI] 2b-3); 8) Informed consent obtained from patients or their legal representatives.

Exclusion criteria

Exclusion criteria: 1)Complete clinical recovery after rapid reperfusion; 2) Allergy to contrast agents; 3)Pregnant or lactating women; 4)Current participation of another clinical trials or has participated in other clinical trials deemed to impact the results of this trial in the 30 days preceding trial inclusion; 5)CT or MRI evidence of the following conditions: a. brain tumors with imaging mass effect; b. intracranial aneurysm or arteriovenous malformation; c. bilateral strokes or multiple intracranial occlusions; d. intracranial hemorrhage; 6) Refractory hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg); 7) Presence of malignancy; 8) Admission laboratory values: glucose 22.2 mmol/L (400 mg/dL); platelet count <90 × 10^9/L; hemoglobin <60 g/L; 9) Chronic renal failure requiring hemodialysis or peritoneal dialysis; 10) History of stroke in the prior 3 months; 11) History of any acupuncture treatment in the prior 3 months; 12) Life expectancy <6 months due to advanced comorbid disease; 13)Follow-up is not expected to be completed; 14) Unable to administer acupuncture due to local skin infection at or near the acupoints, limb defects, or other conditions; 15) Have implanted or plan to implant electronically charged medical device (e.g,Cardiac pacemakers) during the electroacupuncture treatment;

Design outcomes

Primary

MeasureTime frame
mRS score 0 to 1 at 90 (±7) days;

Secondary

MeasureTime frame
mRS score 0 to 2 at 90 (±7) days;Ordinal mRS shift;NIHSS score at 7 days or early discharge;Health-related quality of life [EQ-5D] at 90 (±7) days;

Countries

China

Contacts

Public ContactWang Yuting

Chengdu University of Traditional Chinese Medicine

yutingwang1991@outlook.com18502841879

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026